Whether migraine headache and migraine aura share common pathophysiological mechanisms remains to be understood. Cilostazol causes cAMP accumulation and provokes migraine-like headache in migraine patients without aura. We investigated if cilostazol induces aura and migraine-like headache in patients with migraine with aura and alters peripheral endothelial function and levels of endothelial markers. In a randomized, double-blinded, placebo-controlled crossover study, 16 patients with migraine with aura (of whom 12 patients exclusively had attacks of migraine with aura) received 200 mg cilostazol (Pletal Õ ) or placebo on two separate days.
Introduction
The association between the migraine headache and the migraine aura is not fully understood, and whether migraine with and without aura are two distinct disorders is subject to controversy. The initiating mechanisms of both migraine headache and migraine aura are complex and it remains to be understood if migraine headache and aura share initiating factors. Signalling pathways mediated by cAMP and cGMP play a significant role in initiating migraine-like headache (Thomsen et al., 1994; Kruuse et al., 2003; Guo et al., 2014) . The migraine aura phase is believed to be evoked by cortical spreading depression, characterized by a selfpropagating wave eliciting a band of depolarization that spreads across the cerebral cortex, closely followed by hypoperfusion (Lauritzen, 1994; Ayata, 2010) . The cortical spreading depression may induce the subsequent migraine headache by yet unknown pathways activating the trigeminovascular system (Bolay et al., 2002; Zhang et al., 2010 Zhang et al., , 2011 .
Cilostazol, a selective inhibitor of cAMP-degrading phosphodiesterase 3 (PDE3) used for secondary prevention of stroke, induces headache in healthy subjects (Birk et al., 2006) and migraine-like headache in migraine patients (Guo et al., 2014) . Cilostazol is suggested as a tool for further investigations into the migraine pathophysiology in line with the previously applied glyceryl trinitrate (Christiansen et al., 1999; Afridi et al., 2004) . However, does cilostazolinduced migraine-like headache reflect the 'real-life' initiating mechanisms and can it induce an aura phase in patients prone to migraine with aura? Although only few migraine provocation studies have been done in migraine with aura patients (Bonuso et al., 1989; Christiansen et al., 1999; Afridi et al., 2004; Hansen et al., 2010) and none of these have been able to elicit migraine aura consistently, it is of great interest to disclose a possible common pathway to the aura and migraine phases of the attack, and to determine whether such a pathway may involve the signalling molecules known to be important in induction of migraine-like headache, i.e. cAMP and cGMP.
In addition, migraine with aura is associated with an increased sensitivity to ischaemia (Eikermann-Haerter et al., 2012) and risk of stroke, especially among young females (Etminan et al., 2005; Schurks et al., 2009) . Endothelial dysfunction has been proposed to contribute to this migrainestroke association (Sacco et al., 2008; Bigal et al., 2009; Kurth et al., 2012) , although a recent systematic review did not find endothelial dysfunction to be of importance in migraine with aura subjects (Butt et al., 2015) . However, increased levels of endothelial biomarkers in migraine with aura subjects were reported, which could suggest subtle changes in the endothelium (Butt et al., 2015) .
In the present randomized, double-blinded, placebocontrolled crossover study, we investigated if cilostazol induced aura and migraine-like headache in patients with migraine with aura and changed peripheral endothelial function and levels of endothelial markers. Further, we examined whether baseline peripheral endothelial function and endothelial markers were altered in migraine with aura patients.
Materials and methods

Participants
Sixteen patients suffering from migraine with aura, as defined by the International Headache Society (IHS) Criteria (Headache Classification Committee of the International Headache Society, 2013), were enrolled in the study. Participants were recruited among the hospital staff and through specific patient recruitment websites from November 2014 to June 2015. Exclusion criteria were: age 518 and 450 years; weight 560 and 495 kg; any other type of headache, except tension-type headache £4 days per month; attack frequency of migraine with aura 52 and 412 every year; history of cardio-or cerebrovascular diseases; hypertension (systolic blood pressure 4140 mmHg or diastolic pressure 490 mmHg); hypotension (systolic blood pressure 590 mmHg or diastolic pressure 550 mmHg); any daily intake of medication, including prophylactic migraine treatment, except oral contraceptives; pregnancy and lactation. A full medical history, physical examination, ECG, and vital signs (heart rate and blood pressure) were obtained on the day of recruitment. All participants provided written informed consent before inclusion.
This study was approved by the Ethics Committee of Copenhagen (H-3-2013-166) , the Danish Data Protection Agency, and the Danish Medicines Agency and conducted in accordance with the Declaration of Helsinki of 1964, as revised in 2008. In addition, this study was registered at ClinicalTrials.gov (NCT02253004).
Design and experimental protocol
In this randomized, double-blinded placebo-controlled crossover study, patients suffering from migraine with aura were randomly assigned to receive 200 mg cilostazol (Pletal Õ , Otsuka Pharmaceutical) or placebo (lactose, potato starch, gelatin, magnesium stearate, talcum) in an opaque gelatine capsule on two experimental days separated by at least 5 days. The Capital Region Hospital Pharmacy performed the balanced randomization, in which half of the participants received cilostazol and the other half placebo on the first day and crossed over on the second day.
On both study days, the participants arrived at the clinic at 08:00 am, free from headache and fasting for at least 8 h. Intake of medication, except oral contraceptives was not allowed 12 h before the start of the study. The experiment was postponed if participants experienced headache on the study day before drug administration or had suffered from a migraine attack within 72 h prior to the start of the study. All measurements were performed in a quiet room with a temperature of 22-24 C. Participants were placed in a supine position and a venous catheter was inserted in the antecubital vein for collection of blood samples. After 30 min of rest, blood pressure, heart rate, and ECG were monitored, baseline blood samples were collected, and peripheral endothelial function and arterial stiffness were measured. Participants then received either 200 mg cilostazol or placebo; aura and headache intensity and characteristics were recorded every 15 min until 120 min after drug administration. Subsequently, a second measurement of peripheral endothelial function, arterial stiffness, blood pressure, heart rate, and ECG was done and blood samples collected.
Aura, headache and migraine-like attack criteria
The development, duration, and characteristics of visual, sensory, or speech disturbances were recorded using a validated diagnostic aura diary (Russell et al., 1994) . Headache intensity was scored on a verbal scale from 0 to 10; a score of 1 represented a very mild headache (including a feeling of pressing or throbbing), 5 a headache of moderate intensity, and 10 the worst headache imaginable (Iversen et al., 1989) . Headache characteristics and accompanying symptoms were also recorded as well as premonitory symptoms [defined as 'symptoms preceding and forewarning of a migraine attack by 2-48 h, occurring before the aura in migraine with aura and before the onset of pain in migraine without aura' (Headache Classification Committee of the International Headache Society, 2013)], adverse events, and if the reported headache mimicked their spontaneous migraine attacks. After discharge from the hospital, participants continued these recordings by a self-administered questionnaire every hour until 13 h after drug administration or until bedtime. Participants were allowed to treat headache with their usual migraine treatment or with over-the-counter pain medication.
Experimentally induced migraine by pharmacological intervention cannot fulfil strict IHS criteria (Schytz et al., 2009; Guo et al., 2014) . Therefore, we defined a migraine-like attack, induced 0-13 h after administration of cilostazol, if one of the two following criteria was met:
(i) Headache fulfilling criteria C and D for migraine without aura according to the IHS criteria: C. Headache has at least two of the following characteristics: unilateral location; pulsating quality; moderate to severe pain intensity (equal to 54 on the verbal scale); aggravation by cough (in-hospital period) or causing avoidance of routine physical activity (out-hospital period). D. During headache, at least one of the following associated symptoms: nausea and/or vomiting; photophobia and phonophobia. (ii) Headache described as mimicking usual migraine attack and treated with acute migraine medication.
Peripheral endothelial function and arterial stiffness
Peripheral endothelial function and arterial stiffness were assessed by peripheral arterial tonometry (PAT) using a non-invasive finger plethysmograph (EndoPAT2000; Itamar Medical Ltd.). The EndoPAT2000 evaluates peripheral endothelial function by obtaining pulse wave amplitude (PWA) of the index finger via pneumatic finger probes during reactive hyperaemia of the forearm vascular bed (Kuvin et al., 2003) as described previously (Hansen et al., 2017) . Based on pre-and post-occlusion PWA recordings, a reactive hyperaemia index (RHI) was calculated by a computerized, automated algorithm provided by the EndoPAT2000 software and normalized to the concurrent signal from the control arm to reduce potential systemic effects. Arterial stiffness, expressed as an augmentation index, was quantified by a computerized, automated analysis of the arterial waveform and averaged from the PWA during the baseline period. The augmentation index was defined as the difference between the second and first systolic peaks in the arterial waveform, expressed as a percentage of the central pulse pressure. Because of the influence of changes in heart rate on augmentation index, all values were normalized to a heart rate of 75 beats per minute.
Endothelial markers
Soluble endothelial adhesion molecules, including vascular cell adhesion molecule 1 (VCAM1), E-selectin, and vascular endothelial growth factor A (VEGFA) were measured to assess endothelial activation and function (Hwang et al., 1997; Kliche and Waltenberger, 2001; Meigs et al., 2004; Ponthieux et al., 2004) . Samples were analysed using commercially available kits from Mesoscale (V-PLEX Plus Human VCAM-1 Kit, Human ESelectin Kit, and V-PLEX Human VEGF Kit) according to the manufacturer's instructions. Samples were run in duplex and diluted 2-fold in Diluent 41 prior to measurement. Data were analysed using MSD Discovery Workbench software. The lower limit of detection was a calculated concentration based on a signal 2.5 standard deviations (SD) above the blank (zero) calibrator.
Statistical analysis
All values are presented as means with SD unless otherwise stated. Sample size was chosen based on the results of previous similar headache induction studies in migraine patients (Lassen et al., 2002; Kruuse et al., 2003; Schytz et al., 2009; Hansen et al., 2010; Guo et al., 2014) and a reliability study of the EndoPAT (McCrea et al., 2012) .
Primary outcome measures were incidence of aura and migraine-like attacks and headache intensity. Secondary outcome measures were incidence of headache, endothelial function, arterial stiffness, and endothelial markers. The incidence of aura, migraine-like attacks, and headache after cilostazol and placebo was compared using Fisher's exact test. Area under the curve (AUC), calculated according to the trapezium rule (Matthews et al., 1990) , was applied as a summary measure to analyse the difference between treatments. Differences in AUC for headache intensity were tested with the Wilcoxon signed rank test. Treatment effects for RHI, augmentation index, and endothelial markers in blood were assessed by calculating the difference before and after drug administration (delta-values) and comparing these values for placebo and cilostazol administration using paired t-test.
All statistical analyses were performed with SAS statistical software (SAS 9.4, SAS Institute, Cary, North Carolina, USA). A two-sided P-value 5 0.05 was considered statistically significant.
Data availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Results
Sixteen patients [14 females, two males; mean age 25 (range 18-39)] were included in the study. All patients completed both study days. In their spontaneous attacks, 12 patients experienced aura symptoms preceding every headache phase of migraine, and four patients experienced both migraine with and without aura attacks. The frequency of spontaneous migraine with aura attacks ranged from 2 to 12 per year; all patients usually experienced visual aura. In addition, five patients also experienced sensory aura and two patients had symptoms of aphasia.
Headache and migraine-like attacks
The clinical characteristics of headache and associated symptoms during the 13 h observation period after administration of cilostazol and placebo are shown in Table 1 . Figure 1 displays the headache intensity during the 13 h observation period after administration of cilostazol and placebo. Fourteen patients (88%) experienced headache after intake of cilostazol compared with six patients (38%) after placebo (P = 0.009). The headache in 12 patients (75%) after cilostazol and one patient (6%) after placebo fulfilled the criteria for migraine-like attacks (P = 0.0002).
After cilostazol administration, the median time: (i) to fulfilment of criteria for migraine-like attacks was 5.5 h (range 2-10); (ii) for the headache to mimic a spontaneous migraine headache was 3 h (range 1-6); and (iii) to peak headache was 6 h (range 0-11).
The area under the curve for headache intensity during the observation period was significantly larger after cilostazol compared with placebo (P 5 0.0001). Likewise, the Localization/quality (throb = throbbing; pres = pressing)/intensity/aggravation (by cough during in-hospital phase or by movement during out-hospital phase).
b Nausea/photophobia/phonofobia. Bilat = bilateral. median peak headache intensity was significantly higher after cilostazol (5, range 0-10) compared with placebo (0, range 0-6) (P = 0.0005).
During the observation period, seven patients experienced neck stiffness after cilostazol compared with one patient after placebo. Two patients also reported unusual tiredness and one patient mood swings after cilostazol. These symptoms did not fulfil the criteria for a premonitory symptom in any of the patients. No patients reported adverse events such as palpitations, flushing, or dizziness on either study days.
Eleven patients took their usual medication to treat their headache on the cilostazol day. Five patients responded well to their usual migraine treatment, mainly paracetamol and non-steroidal anti-inflammatory drugs. The six patients, who did not respond well to their usual migraine treatment, reported that during spontaneous migraine attacks medication only occasionally relieved their headache. No patients took medication on the placebo day.
Aura
Aura symptoms and subsequent headache were elicited in one patient after administration of cilostazol and one patient after placebo.
Patient 2 reported visual aura with right-sided flickering light spots 15 min after intake of placebo. The symptoms lasted $20 min. Headache was reported 5 min after termination of the aura phase and fulfilled the criteria for migraine-like attacks. Apart from the duration of the period between termination of the aura phase and onset of headache (normally 30 min), the patient described the symptoms as being similar to those of a spontaneous migraine with aura attack.
Patient 12 reported visual aura with left-sided homonymous scotoma 4.5 h after cilostazol intake. The symptoms lasted $15 min. Headache was reported immediately after termination of the aura phase and fulfilled the criteria for migraine-like attacks. The patient described these symptoms as being similar to those of a spontaneous migraine with aura attack.
Endothelial function, arterial stiffness, and endothelial markers RHI, augmentation index, and blood markers of endothelial function measurements according to time and treatment are shown in Table 2 . There was no statistically significant difference in RHI (P = 0.27) or augmentation index (P = 0.36) between cilostazol and placebo. Similarly, no significant changes in endothelial markers were detected between treatments.
The baseline RHI in migraine with aura patients was similar to that reported in 20 healthy subjects in our previous study (unpaired t-test, P = 0.16) (Hansen et al., 2017) .
Discussion
In this randomized, double-blinded, placebo-controlled crossover study, we investigated the aura-and headacheinducing effect of cilostazol and the effect on peripheral endothelial function and endothelial markers after cilostazol administration in migraine with aura patients. Our analysis yielded three major findings. First, cilostazol did not induce aura in migraine with aura patients. Second, cilostazol induced headache in 14 patients (88%); the headache in 12 patients (75%) fulfilled the criteria for migraine-like attacks. Third, cilostazol did not significantly alter peripheral endothelial function, as assessed by peripheral arterial tonometry, arterial stiffness, or the endothelial markers, E-selectin, VEGFA, and VCAM1.
Over the past two decades, human migraine models have been developed to elucidate the initiating mechanisms of migraine. Thus, studies of experimental migraine induction have revealed important signalling pathways involved in the initiation of migraine headache. A human model of migraine aura, on the other hand, has not yet been established, although a great deal of effort has been spent in the development of such a model. Several methods for an experimental provocation of migraine aura have been attempted, including visual stimulation, physical activity, and induction by pharmaceutical drugs, with rather disappointing results (Lindblad et al., 2017) .
Signalling pathways involving the second messenger molecules, cAMP and cGMP, are essential in migraine headache initiation, and the trigeminovascular system may include common relay points such as in the trigeminal ganglion (Nordgaard et al., 2014) . Previous studies have consistently shown that compounds increasing cAMP [calcitonin gene-related peptide (CGRP), PACAP38, and cAMP-degrading PDE3 inhibitor cilostazol] (Lassen et al., 2002; Schytz et al., 2009; Guo et al., 2014) and cGMP (nitric oxide donors and cGMP-degrading PDE5 inhibitor sildenafil) (Thomsen et al., 1994; Kruuse et al., 2003) cause migraine-like attacks in subjects with migraine without aura (Fig. 2) . However, the role of these signalling pathways in migraine with aura is largely unknown, as the effect of these compounds has been sparsely investigated in patients with migraine with aura. In a study by Hansen et al. (2010) including 14 migraine with aura patients, CGRP triggered migraine-like attacks in eight (56%) and aura symptoms in four patients (28%). Christiansen and colleagues (1999) found that glyceryl trinitrate induced migraine-like attacks, but not aura, in 10 of 12 migraine with aura patients (83%). In another study, glyceryl trinitrate triggered migraine attacks fulfilling IHS criteria in 14 of 21 (67%) migraine with aura patients, but visual aura in one patient only (Afridi et al., 2004) . However, this is the first study to investigate the aura-and headache-inducing effect of the selective PDE3 inhibitor cilostazol in patients with migraine with aura. Do PDE3 and cAMP play a role in the initiation of migraine aura? Our results indicate that this may not be the case. We found that oral administration of cilostazol induced migraine aura in one patient only, though one patient also developed this phenomenon after placebo intake. Although the reported aura symptoms and subsequent headache characteristics were similar to those experienced by the patient during spontaneous migraine with aura attacks, the low proportion of patients developing aura following cilostazol administration makes this drug inadequate as a useful tool for the provocation of migraine aura. Our findings indicate that accumulation of cAMP by selective PDE3 inhibition may not play any role in the initiation of migraine aura. Interestingly, in a case report, the selective PDE5 inhibitor, tadalafil, consistently induced typical visual aura without headache 72 h after administration in a patient with no history of migraine or significant visual disturbances (Dinn and Wall, 2006) . Whether selective PDE5 inhibitors may induce aura symptoms in patients with migraine with aura has yet to be explored.
Despite the absent aura-inducing effect of cilostazol, this selective PDE3 inhibitor provoked migraine-like attacks in 12 migraine with aura patients mimicking the headache phase during their usual migraine attacks, but without premonitory symptoms as described for glyceryl trinitrate provoked headaches (Christiansen et al., 1999) . Interestingly, the majority of these patients always experienced aura symptoms preceding the headache phase during their spontaneous migraine attacks. A possible explanation to this finding may be that cilostazol activates pathways relevant for the initiation of migraine headache (i.e. intracellular accumulation of cAMP by selective PDE3 inhibition) downstream to the cascade of migraine aura initiation and propagation. Despite the lack of direct evidence in migraine patients, cortical spreading depression is strongly believed to be the underlying mechanism of migraine aura (Lauritzen, 1994; Ayata, 2010) and has been proposed as a trigger for migraine headache by activation of the trigeminovascular system causing migraine headache (Bolay et al., 2002; Zhang et al., 2010 Zhang et al., , 2011 . In animal models, cortical spreading depression can be induced by pinprick or potassium administration on the brain surface, but no spontaneous equivalents of these experimental procedures have been described. What, then, triggers migraine aura? The answer to this question is essential for fully understanding the role of aura in migraine pathophysiology and a valid human migraine aura model may provide some answers. Such may also shed light on the enigmatic association between migraine, particularly migraine with aura, and stroke. Migraine with aura has consistently been associated with an increased risk of ischaemic stroke and the exact underlying mechanisms have not been identified yet. In this regard, the findings of a recent study investigating the aura-inducing potential of hypoxia in patients with migraine with aura are of great interest. Arngrim and colleagues (2016) found that migraine aura may be induced by hypoxia, though only 3 of 15 patients developed aura and additional four possible aura. In addition, hypoxia has been shown to induce cortical spreading depression in animal models (Takano et al., 2007; Mane and Muller, 2012) . These findings could point to an increased sensitivity to minor alterations in blood flow or reduced oxygen in migraine with aura patients. We hypothesized that cilostazol may alter peripheral endothelial response in migraine with aura patients. In general, the baseline endothelial response was similar to that reported in healthy subjects and baseline levels of endothelial markers were not altered. We found no effect of cilostazol on peripheral endothelial function or endothelial markers in migraine with aura patients possibly reflecting that an already well-functioning endothelium may not be improved by a drug such as cilostazol. Overall, our findings do not support a generally reduced endothelial function in migraine with aura patients; however, post hoc power analyses showed our study to be underpowered for these outcomes.
Limitations
The findings of this study should be viewed in the context of a number of limitations. The majority of studies on experimental provocation of migraine aura included patients who exclusively had attacks of migraine with aura. In our study, we included 16 patients with migraine with aura, of whom 12 patients exclusively had attacks of migraine with Figure 2 Experimental provocation of migraine headache and migraine aura in migraine patients. A green arrow indicates that this compound provokes migraine headache and/or migraine aura. A white arrow with red strikethrough indicates that this compound does not provoke migraine headache and/or migraine aura. References for each trigger: hypoxia (Arngrim et al., 2016) ; visual stimulation and/or physical activity (Cao et al., 1999 (Cao et al., , 2002 Hougaard et al., 2013) ; glyceryl trinitrate (GTN) (Bonuso et al., 1989; Christiansen et al., 1999; Afridi et al., 2004; Sances et al., 2004) ; CGRP (Hansen et al., 2010) ; cilostazol (Guo et al., 2014) ; PACAP38 (Schytz et al., 2009) ; sildenafil (Kruuse et al., 2003) . aura. Thus, four patients experienced both migraine with aura and migraine without aura attacks, though the majority of these primarily were migraine with aura attacks. Ideally, patients should exclusively experience attacks of migraine with aura to maximize the possibility of aura provocation and to assess the relation between migraine aura and migraine headache. However, restricting our study population to patients, who exclusively had attacks of migraine with aura yielded similar findings as the main analyses. As in other migraine-provoking studies, the majority of the study population in our study comprised females. Although the distribution reflects the gender composition in patients with migraine in general, the generalizability of the model for males may be limited. Further, although peripheral endothelial function measurements by peripheral arterial tonometry using EndoPAT2000 are easy to perform, require minimal training, and have a low interand intra-observer variability (Flammer et al., 2012) , the main disadvantage is the influence of environmental conditions and sympathetic tone on the peripheral circulation of arterioles. In a recent study, however, we found moderate to substantial reliability in day-to-day measurements using EndoPAT2000 in healthy subjects and patients with stroke (Hansen et al., 2017) . In addition, the data on endothelial markers should be interpreted with caution as some of these could not be measured in all blood samples. Furthermore, statistical power was limited as post hoc power analyses reveal power levels of 7-32% to detect a difference in the level of endothelial markers. Finally, in the current study we included only E-selectin, VEGFA, and VCAM1, though a variety of other endothelial markers, such as ICAM1, asymmetric dimethylarginine, and interleukins, may apply.
Conclusion
Increase in cAMP by cilostazol does not induce aura in patients with migraine with aura. Without the original trigger mechanisms, migraine with aura patients, even those who exclusively report attacks of migraine with aura, only experience a migraine-like headache after cilostazol. These findings further support dissociation between the aura and headache phase in migraine with aura patients with a yet unknown trigger for the aura and link between aura and headache. In addition, a general endothelial dysfunction in migraine with aura patients as a factor in a possible increased stroke risk is not substantiated by the current findings.
